Nicotine pharmacokinetics and subjective responses after using nicotine pouches with different nicotine levels compared to combustible cigarettes and moist smokeless tobacco in adult tobacco users.

Plain-language guide to PMID 35869988 (2022): single-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 35869988
Journal: Psychopharmacology
Year: 2022
Study type: Randomized Controlled Trial
Authors: Liu J et al. (7 authors)
DOI: 10.1007/s00213-022-06172-y

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

The researchers used a randomized, in-clinic, partial single-blind, 7-way crossover design to assess nicotine PK and subjective effects in dual users of cigarettes and MST.

Why It Was Studied

Oral tobacco-derived nicotine products include on!® nicotine pouches (NPs) which are tobacco-leaf free and available in multiple flavors and nicotine levels.

However, the dependence potential of NPs is not established.

Who Took Part

The age groups tagged for this paper are adults.

How the Study Was Run

The researchers set it up as a randomized, single-blind and crossover study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

In this single-blind Therapeutic nicotine (patch, non-peptide) study one party knew the assignments and the other did not.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

What Was Measured

Oral tobacco-derived nicotine products include on!® nicotine pouches (NPs) which are tobacco-leaf free and available in multiple flavors and nicotine levels.

Therefore, the researchers characterized the abuse potential of NPs with different nicotine levels compared to cigarettes and MST.

PubMed files the paper under topics including Electronic Nicotine Delivery Systems, Nicotine, Tobacco Products and Tobacco, Smokeless.

The authors tagged it with the keywords Abuse potential, Dependence potential, Nicotine pouches, Novel oral tobacco products, Oral tobacco–derived nicotine products and Subjective measures.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.